Evidence map›Paper›PMID 31959335›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2020

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

G Curigliano, D Lenihan, M Fradley, S Ganatra, A Barac, A Blaes, J Herrmann, C Porter, A R Lyon, P Lancellotti and 20 more

Open access · bronzeAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 547 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
547citing papers in PubMed, 14 pooled it
92.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

547 citing papers in PubMed, 14 syntheses or guidelines pooled it, 963 citations in OpenAlex.

  1. Structured exercise and cardiac outcomes during anthracycline or anti-HER2 therapy in breast cancer: systematic review and meta-analysis of randomized trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024
    Pooled it
  12. Brazilian Guideline on Menopausal Cardiovascular Health - 2024.Arquivos brasileiros de cardiologia · 2024
    Guideline
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Article

487 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 20 institutions in 7 countries.

G CuriglianoEuropean Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy.
D LenihanCardiovascular Division, Cardio-Oncology Center of Excellence, Washington University Medical Center, St. Louis, USA.
M FradleyCardio-oncology Program, Division of Cardiovascular Medicine, Morsani College of Medicine and H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, USA.
S GanatraCardio-Oncology Program, Lahey Medical Center, Burlington.
A BaracCardio-Oncology Program, Medstar Heart and Vascular Institute and MedStar Georgetown Cancer Institute, Georgetown University Hospital, Washington DC, USA.
A BlaesDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, USA.
J HerrmannMayo Clinic College of Medicine, Rochester, USA.
C PorterUniversity of Kansas Medical Center, Lawrence, USA.
A R LyonRoyal Brompton Hospital and Imperial College, London, UK.
P LancellottiGIGA Cardiovascular Sciences, Acute Care Unit, Heart Failure Clinic, CHU Sart Tilman, University Hospital of Liège, Liège, Belgium.
A PatelMorsani College of Medicine, University of South Florida, Tampa, USA.
J DeCaraMedicine Section of Cardiology, University of Chicago, Chicago, USA.
J MitchellWashington University Medical Center, St. Louis, USA.
E HarrisonHCA Memorial Hospital and University of South Florida, Tampa, USA.
J MoslehiVanderbilt University School of Medicine, Nashville, USA.
R WittelesDivision of Cardiovascular Medicine, Falk CVRC, Stanford University School of Medicine, Stanford, USA.
M G CalabroDepartment of Anesthesia and Intensive Care, IRCCS, San Raffaele Scientific Institute, Milan, Italy.
R OrecchiaEuropean Institute of Oncology IRCCS, Milan, Italy.
E de AzambujaInstitut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium.
J L ZamoranoUniversity Hospital Ramon y Cajal, Madrid, Spain.
R KroneDivision of Cardiology, Washington University, St. Louis, USA.
Z IakobishviliClalit Health Services, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
J CarverDivision of Cardiology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, USA.
S ArmenianDepartment of Population Sciences, City of Hope Comprehensive Cancer Center, Duarte, USA.
B KyUniversity of Pennsylvania School of Medicine, Philadelphia, USA.
D CardinaleCardioncology Unit, European Institute of Oncology, IRCCS, Milan, Italy.
C M CipollaCardiology Department, European Institute of Oncology, IRCCS, Milan, Italy.
S DentDuke Cancer Institute, Duke University, Durham, USA.
K JordanDepartment of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.
ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
European Institute of Oncology · ITWashington University Medical Center · USCity of Hope · USDuke University · USGeorgetown University · USHeidelberg University · DEHospital of the University of Pennsylvania · USHospital Universitario Ramón y Cajal · ESImperial College London · GBLahey Medical Center · USMayo Clinic · USMemorial Hospital · USMoffitt Cancer Center · USStanford University · USTel Aviv University · ILUniversité Libre de Bruxelles · BEUniversity of Chicago · USUniversity of Kansas Medical Center · USUniversity of Liège · BEUniversity of Milan · IT

Funding

TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) TrialR01CA233610 · NCI · MAYO CLINIC ROCHESTER · PI HERRMANN, JOERG, RUDDY, KATHRYN JEAN · 2019 to 2024
$4.3M
NCI NIH HHS R01 CA233610
6 · The paper itself

Abstract

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.

Indexed as

Antineoplastic AgentsHeart DiseasesNeoplasmsHumansMedical OncologyAntineoplastic Agentscardiac diseasecardiovascular toxicityClinical Practice Guidelinesdiagnosisrecommendations

Identifiers

PMID31959335
PMCPMC8019325
OpenAlexW2999536665

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.